Mosunetuzumab (NCT06563505)

Name: Mosunetuzumab trial for Lymphoma (NCT06563505)
Uploaded: 2026-10-31T06:42:16.250Z
Duration: 1 min 15 s
Description: Mosunetuzumab trial for Lymphoma (NCT06563505). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06563505.

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma: a one-minute explainerNCT065635051 min

Mosunetuzumab trial for Lymphoma (NCT06563505). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage two to four marginal-zone lymphoma, or unclassifiable indolent B-cell lymphoma, that returned or resisted their latest treatment. Prior treatment must include a CD20 antibody, and systemic therapy must be needed.

The idea: combine mosunetuzumab and zanubrutinib. Mosunetuzumab connects T cells to CD20-bearing B cells to support immune attack. Zanubrutinib blocks BTK growth and survival signals. Researchers assess complete responses and safety. All participants receive the combination; there is no comparison group.

This phase 2 study plans 36 patients. Dai Chihara leads MD Anderson's recruiting Houston site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.